A breakthrough cancer treatment prevents the recurrence of leukaemia for at least 10 years, a new study shows.
The paper, published in the journal Nature, showed two patients who were followed for a decade after beginning a trial of Chimeric Antigen Receptor (CAR) T-cell therapy in 2010 have been in remission since starting.
